Trials / Completed
CompletedNCT06487572
A Study to Assess Pharmacokinetic Exposures Following Intravenous and Subcutaneous Administration of Risankizumab in Healthy Participants
A Phase 1, Open-label Study to Assess PK Exposures Following Intravenous and Subcutaneous Administration of Risankizumab in Healthy Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 60 (actual)
- Sponsor
- AbbVie · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
The objective of this study is to compare pharmacokinetic exposures following intravenous and subcutaneous administration of Risankizumab.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Risankizumab | Intravenous (IV) Infusion |
| DRUG | Risankizumab | Subcutaneous (SC) Injection |
Timeline
- Start date
- 2024-07-23
- Primary completion
- 2025-02-07
- Completion
- 2025-02-07
- First posted
- 2024-07-05
- Last updated
- 2025-02-18
Locations
2 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT06487572. Inclusion in this directory is not an endorsement.